4-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-morpholine | 294649-44-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-morpholine
• 英文别名: 4-[5-(4-Methylpiperazin-1-yl)-2-nitrophenyl]morpholine
• CAS: 294649-44-8
• 化学式: C₁₅H₂₂N₄O₃
• mdl: MFCD00402787
• 分子量: 306.365
• InChiKey: KKBSYQCICYAIOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  64.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-morpholine 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Discovery of novel FMS kinase inhibitors as anti-inflammatory agents

  摘要：

  The optimization of the arylamide lead 2 resulted in identification of a highly potent series of 2,4-disubstituted arylamides. Compound 8 (FMS kinase IC50 = 0.0008 mu M) served as a proof-of-concept candidate in a collagen-induced model of arthritis in mice. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.059
• 作为产物：
  描述：

  N-甲基哌嗪 、 4-(5-氯-2-硝基苯基)-吗啉 生成 4-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-morpholine
  参考文献：
  名称：

  Regular Trends in Nucleophilic Substitutions in 2-Alkylamino-4-chloronitrobenzenes

  摘要：

  研究了位置 2 上的取代基对 2-烷基氨基-4-氯硝基苯在不同性质的 N-亲核物亲核取代中的反应性的影响。

  DOI：

  10.1007/s11178-005-0146-6

文献信息

• Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1676842A1

  公开（公告）日：2006-07-05

  The present invention relates to nitro-substituted phenyl-piperazine compounds of general formula I, a process for their preparation, medicaments comprising said nitro-substituted phenyl-piperazine compounds as well as the use of said nitre-substituted phenyl-piperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.

  本发明涉及一般式I的硝基取代苯基哌嗪化合物，其制备方法，包含所述硝基取代苯基哌嗪化合物的药物，以及利用所述硝基取代苯基哌嗪化合物制备药物，该药物特别适用于预防和/或治疗至少部分通过5-HT6受体介导的疾病或疾病。
• Inhibitors of c-fms kinase
  申请人：Illig R. Carl

  公开号：US20060100201A1

  公开（公告）日：2006-05-11

  The invention relates to compounds of Formula I: wherein A, X, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的化合物：其中A、X、R2和W在说明书中设置，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，它们抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了利用公式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症、Paget病和其他骨吸收介导的疾病，包括关节炎、假体失效、骨溶性肉瘤、骨髓瘤和肿瘤转移至骨骼。
• Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1902733A1

  公开（公告）日：2008-03-26

  The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种由至少一种具有 5-HT6 受体亲和力的化合物和至少一种 NMDA 受体配体组成的活性物质组合、一种包含所述活性物质组合的药物，以及使用所述活性物质组合制造药物。
• WO2006/47504
  申请人：——

  公开号：——

  公开（公告）日：——
• AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE
  申请人：Janssen Pharmaceutica NV

  公开号：EP1807407B1

  公开（公告）日：2009-07-29